Last reviewed · How we verify

bupropion and transdermal patch — Competitive Intelligence Brief

bupropion and transdermal patch (bupropion and transdermal patch) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Norepinephrine-dopamine reuptake inhibitor. Area: Mental health, Smoking cessation.

phase 3 Norepinephrine-dopamine reuptake inhibitor Norepinephrine transporter, Dopamine transporter Mental health, Smoking cessation Small molecule Live · refreshed every 30 min

Target snapshot

bupropion and transdermal patch (bupropion and transdermal patch) — US Department of Veterans Affairs. Bupropion is a norepinephrine-dopamine reuptake inhibitor, which increases the levels of these neurotransmitters in the brain.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
bupropion and transdermal patch TARGET bupropion and transdermal patch US Department of Veterans Affairs phase 3 Norepinephrine-dopamine reuptake inhibitor Norepinephrine transporter, Dopamine transporter
bupropion + lozenge bupropion + lozenge University of Wisconsin, Madison marketed Antidepressant + nicotine replacement therapy Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
bupropion + nicotine gum bupropion + nicotine gum University of Wisconsin, Madison marketed Combination smoking cessation therapy (antidepressant + nicotine replacement) Norepinephrine transporter, dopamine transporter (bupropion); nicotinic acetylcholine receptors (nicotine)
Nefopam administration and prelevment Nefopam administration and prelevment University Hospital, Rouen marketed Non-opioid analgesic; monoamine reuptake inhibitor Norepinephrine transporter, dopamine transporter, serotonin transporter
bupropion & Citalopram bupropion & Citalopram University of Colorado, Denver marketed Antidepressant combination (NDRI + SSRI) Norepinephrine transporter, dopamine transporter, serotonin transporter
Combination Bupropion + NRTs Combination Bupropion + NRTs Brentwood Biomedical Research Institute marketed Antidepressant + nicotine replacement combination Norepinephrine transporter, dopamine transporter; nicotinic acetylcholine receptors
AXS-05 AXS-05 Axsome Therapeutics, Inc. marketed Combination antidepressant (NMDA antagonist + norepinephrine-dopamine reuptake inhibitor) Sigma-1 receptor, NMDA receptor, norepinephrine transporter, dopamine transporter

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Norepinephrine-dopamine reuptake inhibitor class)

  1. Breath of Life International Pharma Ltd · 1 drug in this class
  2. Hospital Universitario de Canarias · 1 drug in this class
  3. Iowa City Veterans Affairs Medical Center · 1 drug in this class
  4. Pablo Rodríguez del Rio · 1 drug in this class
  5. Pfizer · 1 drug in this class
  6. US Department of Veterans Affairs · 1 drug in this class
  7. VA Office of Research and Development · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). bupropion and transdermal patch — Competitive Intelligence Brief. https://druglandscape.com/ci/bupropion-and-transdermal-patch. Accessed 2026-05-15.

Build your own brief

Pick any drug + add comparators: